Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYC siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
MYC siRNA refers to small interfering RNA (siRNA) molecules designed to target and silence the expression of the MYC oncogene (specifically c-MYC mRNA) via the RNA interference (RNAi) pathway. MYC is a highly sought-after but historically 'undruggable' transcription factor that is frequently overexpressed or deregulated in a wide variety of human cancers, driving cell proliferation, metabolic reprogramming, and therapeutic resistance. By binding complementarily to MYC mRNA, MYC siRNA guides the RNA-induced silencing complex (RISC) to cleave and degrade the transcript, thereby reducing MYC protein levels. Various delivery vehicles, such as lipid nanoparticles (LNPs), are utilized to protect the siRNA from nuclease degradation and facilitate intracellular delivery. While several preclinical and clinical-stage candidates (such as Dicerna's DCR-MYC) have been developed, targeting MYC via siRNA remains an active area of oncology research.
- Other names
- MYC small interfering RNAc-Myc siRNA
02
Targets
MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on MYC siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYC siRNA.